Absract The aim of the study: to present current data on pathogenesis, clinical picture, methods of diagnostics and differential diagnosis of hyperprolactinemia syndrome. Treatment strategy and the effectiveness and safety of dopamine agonists as the main method of drug therapy of this condition, as well as their implication at the stage of pregravid preparation and during pregnancy, if indicated, were shown in the trial. Materials: literature data of foreign and domestic authors for the period from 1972—2018, including Russian and international guidelines. Methods: Analysis and generalization of literature data. Conclusion: drug therapy of hyperprolactinemia is geared at normalizing prolactin level, restoring ovulatory menstrual cycle and fertility, regression of size of pituitary prolactinoma. It can also be a promising direction in regulation of lipid metabolism, prevention of cardiovascular diseases and pathology of mammary glands, as well as various autoimmune processes.